Twitter Beğeni Hilesi

#Parkinson’s Awareness month honours the resilience of the 10 million people living with Parkinson’s worldwide. We strive to unlock new possibilities for the treatment of neurodegenerative diseases, including Parkinson’s. parkinson.org/parkinsons-awa… #ABCsofPD #TPD #DrugDiscovery

Next week, our Chief Scientific Officer, Louise Modis, will be at the LifeArc Translational Science Summit, where she’ll be presenting on Amphista’s novel degraders from 3:55-4:20pm BST. Register for the event here: translationalsciencesummit.org/home #TranslationalScience

For World #AML Awareness Day, we are united in the fight against AML, a rare aggressive cancer of blood and bone marrow. This year is focused on raising awareness for the #caregivers and the importance of self-care while supporting loved ones with AML. know-aml.com/get-involved/w…

Our Interim CEO, Beverley Carr, Chief Scientific Officer, Louise Modis and Senior Director of Business Development and Operations, John Goodall, will be on the ground in London for the 10th annual LSX Leaders World #Congress on 29-30 April. informaconnect.com/lsx-world-cong… #TPD

May is #NCRM24, a global campaign by AACR to highlight the importance of cancer research. We are progressing a portfolio of next-gen bifunctional protein degraders with the potential to unlock novel treatment options for patients affected by cancer and other severe diseases.

Amphista has been shortlisted for the 2024 Cambridge Independent Science and Technology Awards in the Award for Innovation category! Congratulations to the entire Amphista team and all the other companies and individuals shortlisted. #Shortlisted #DrugDiscovery #TPD #SciTechAwards

Thank you Cambridge Independent for a great evening at the Science and Technology Awards last night. Amphista was shortlisted for The Award for Innovation and while we didn’t win, we were thrilled to be included amongst a strong field of innovators. Congratulations to all finalists!

Today we have unveiled a new mechanism of action for the degradation of BRD9 that is completely differentiated from cereblon- or VHL-based PROTACs. Read the full announcement here: amphista.com/amphista-thera… #DrugDiscovery #Biotech #TargetedProteinDegradation #CeTPD #TPD

ICYMI – Last week, BioCentury covered our unveiling of a new mechanism of action for the degradation of BRD9. Read the full piece by Danielle Golovin here: biocentury.com/article/652493… #BioCentury #DrugDiscovery #Biotech #TargetedProteinDegradation #CeTPD #TPD

June is #Alzheimer’s & Brain Awareness Month. At Amphista, we are committed to unlocking the full potential of #TPD to treat neurodegenerative diseases using our CNS penetrant, bifunctional protein degraders with leading physicochemical properties. alz.org/abam/overview.…

Last week, #AmphistaTherapeutics came together to celebrate our annual Company Day. Reflecting on our progress in 2024 so far, we’re excited about the future as we continue to develop the next generation of targeted protein degraders! #TPD #TeamBuilding #People

At Amphista Therapeutics, we are committed to creating a culture that promotes #Diversity and #Equality, as we stand in solidarity with the LGBTQ+ community. This #PrideMonth we celebrated with a delightful ‘Potluck’ style picnic in the sunshine!

Victoria Lovatt, VP of Intellectual Property at Amphista, recently shared her expertise at the World Intellectual Property Organization (WIPO) Patent Drafting Training Program. Thank you, WIPO, for inviting Victoria to share her expertise and contribute to the next generation of high-quality patent professionals! #TPD

Scott Hughes, our Director of Exploratory Biology, recently presented our new #BRD9 mechanism at the 5th Virtual Bio-Techne Targeted Protein Degradation and Induced Proximity Symposium. Watch here: youtu.be/zsprihcMaXw?si… #DrugDiscovery #Biotech #TPD #InducedProximity

Last week marked Amphista’s Great Big Green Week promoting recycling and environmental awareness through fun activities like biodiversity walks, sustainable travel, and eco-friendly quizzes. #DrugDiscovery #Biotech #TPD

Our team recently enjoyed some delicious ice cream from the wonderful Jack’s Gelato, for a sweet treat this summer. #JacksGelato #GrantaPark #TeamBuilding #Wimbledon #IceCream #TPD #Biotech #DrugDiscovery

Next week, Callum Hamby, Senior Medicinal Chemist, will be attending the XXVIII EFMC International Symposium on Medicinal Chemistry. Looking forward to discussing our next generation #TPD technology, which works through a completely novel mechanism. Be sure to join us in Rome!

We are delighted to announce the #appointment of Antony Mattessich as our new CEO and Board member. In his new role, Antony will be critical in advancing our next gen Targeted Glue™ protein degraders into the clinic and building a robust pipeline. amphista.com/amphista-thera…

Exciting week ahead for the Amphista team! Richard Sherhod, Senior Director of Chemoinformatics & Computational Chemistry, will attend RDKit User Group Meeting in Zurich and James Lynch, Director of Oncology will be at the ESMO - Eur. Oncology Congress in Barcelona. #DrugDiscovery #TPD

Congratulations to the Amphista Avengers for their semi-final win against Nxera’s Hit Finders in the Granta Park Rounders Tournament. Thank you Nxera for the tough game and good sportsmanship. We are looking forward to the final on 17 Sept against Illumina’s The Home Run Hitters!